Home › NDC Lookup › RxCUI directory › RxCUI 1858995

3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector — RxCUI 1858995

Name: 3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector (RxCUI 1858995)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1858995 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1858995

Official name3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asinsulin glargine 100 UNT/ML / lixisenatide 33 MCG/ML per 3 ML Pen Injector; insulin glargine 100 UNT/ML / lixisenatide 33 MCG/ML in 3 ML Pen Injector

FDA products mapped1

Package NDCs mapped2

Reported Medicaid activity (SDUD)4,625 prescriptions · 32 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glargine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Insulin glargine is a long-acting insulin — it's designed to provide a slow, steady background level of insulin over the course of the day, rather than a quick spike like short-act...
What exactly is insulin glargine and why did my doctor prescribe it instead of regular insulin?
You can take insulin glargine at any time of day that works for your routine — morning, evening, whenever. The key is to take it at the same time every single day. Consistency help...
Does it matter what time of day I take my injection?

📖 Read our full Insulin Glargine (rDNA origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin glargine 100 UNT/ML / lixisenatide... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector RxCUI 1858995 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Insulin glargine 274783 IN
- Lixisenatide 1440051 IN
- Insulin glargine / lixisenatide 1858994 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Soliqua 1858996 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Insulin glargine / lixisenatide Pen Injector 1858993 SCDF
- Insulin glargine / lixisenatide Injectable Product 1858992 SCDG
- Insulin glargine / lixisenatide Pen Injector [Soliqua] 1858998 SBDF
- Soliqua Injectable Product 1858999 SBDG
- Pen Injector 1649571 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Insulin glargine 100 UNT/ML 343226 SCDC
- Lixisenatide 0.033 MG/ML 1858991 SCDC
- 3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector [Soliqua] 1859000 SBD
- Insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML [Soliqua] 1858997 SBDC

Showing up to 8 concepts per family — 14 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Insulin glargine 100 UNT/ML SCDC · 343226
Lixisenatide 0.033 MG/ML SCDC · 1858991
Insulin glargine / lixisenatide Pen Injector SCDF · 1858993
Insulin glargine / lixisenatide Injectable Product SCDG · 1858992

Brand-Name Concepts

3 ML insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML Pen Injector [Soliqua] SBD · 1859000
Insulin glargine 100 UNT/ML / lixisenatide 0.033 MG/ML [Soliqua] SBDC · 1858997
Insulin glargine / lixisenatide Pen Injector [Soliqua] SBDF · 1858998
Soliqua Injectable Product SBDG · 1858999
Soliqua BN · 1858996

📦 FDA Products & Package NDCs

1 product · 2 package NDCs

2 package NDCs map to RxCUI 1858995 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00024-5761-01	1 SYRINGE in 1 CARTON (0024-5761-01) / 3 mL in 1 SYRINGE	Soliqua 100/33	Sanofi-Aventis U.S. LLC	2016-11-21
00024-5761-05	5 SYRINGE in 1 CARTON (0024-5761-05) / 3 mL in 1 SYRINGE (0...	Soliqua 100/33	Sanofi-Aventis U.S. LLC	2016-11-21

Observed labelers: Sanofi-Aventis U.S. LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$57.0959

Range $57.0959–$57.0959 · middle 50% $57.0959–$57.0959 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.